Evolution in coeliac disease diagnosis and management

Area of Science:

• Immunology
• Gastroenterology
• Genetics

Background:

• Coeliac disease understanding is evolving beyond a gut-centric model.
• Immune and genetic factors highlight a systemic T cell response to gluten in pathogenesis.
• Limitations of small intestinal histology for diagnosis are increasingly recognized.

Purpose of the Study:

• To review the evolving understanding of coeliac disease pathogenesis.
• To discuss advancements in diagnostic approaches, including serologic methods and novel biomarkers.
• To explore challenges in diagnosis, treatment, and the development of novel therapies for coeliac disease.

Main Methods:

• Review of current literature on coeliac disease immunology, genetics, and diagnostics.
• Analysis of novel biomarkers, such as interleukin-2, for gluten-specific T cell identification.
• Evaluation of challenges in diagnosis, treatment efficacy, and clinical trial design.

Main Results:

• Immune and genetic insights emphasize a systemic T cell response to gluten.
• Serologic diagnosis is gaining accuracy for adults, mirroring findings in children.
• Novel biomarkers show high sensitivity and specificity, potentially eliminating the need for gluten challenges.
• Asymptomatic disease and extra-intestinal manifestations complicate diagnosis.
• The gluten-free diet remains restrictive, with limited data on safe gluten intake thresholds.
• Ongoing symptoms and enteropathy are common, requiring systematic evaluation.
• Slowly-responsive disease and gluten hypersensitivity are emerging concepts.
• No specific drugs for coeliac disease are yet registered, with ongoing research into therapies and clinical trial design.

Conclusions:

• Coeliac disease is increasingly viewed as a systemic T cell-mediated disorder.
• Advancements in biomarkers and serologic testing offer potential for non-invasive diagnosis.
• Significant challenges remain in managing the disease, including treatment adherence and the development of effective therapies.
• Novel immune tools are crucial for advancing clinical trial design and evaluating therapeutic efficacy.